CDK11B

Across TCGA pan-cancer cohorts, CDK11B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDK11B data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CDK11B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CDK11B expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where CDK11B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.944	0.630	.010	35	view →
LSCC	DFS	Median	II,III,IV	1.000	0.841	.007	20	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	18	view →
LUAD	DFS	Tertile	III,IV	0.976	0.426	.002	16	view →
HNSC	OS	Median	II,III,IV	0.808	0.897	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDK11B–CCRCC (OS)

Open the CCRCC breakdown →